Oncolytic Virus Therapy Market Growth, Trends, and Forecast by 2031

Historic Data: 2021-2023   |   Base Year: 2024   |   Forecast Period: 2025-2031

Coverage: Oncolytic Virus Therapy Market covers analysis By Product Type (Vaccinia Virus-based Oncolytic Viruses, HSV-based Oncolytic Viruses, Adenoviruses-based Oncolytic Viruses, Newcastle Disease Virus-based Oncolytic Viruses, Vesicular Stomatitis Virus-based Oncolytic Viruses); Application (Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Brain Tumor, Blood Cancer); End User (Hospitals, Specialty Clinics, Cancer Research Institutes), and Geography (North America, Europe, Asia Pacific, and South and Central America)

  • Report Date : Oct 2025
  • Report Code : TIPRE00014846
  • Category : Life Sciences
  • Status : Upcoming
  • Available Report Formats : pdf-format excel-format
  • No. of Pages : 150
Page Updated: Apr 2025

AI overview of Oncolytic Virus Therapy Market


The Oncolytic Virus Therapy Market is poised for significant expansion, with a projected market size reaching US$ XX million by 2031, reflecting a robust CAGR of 24.5% from 2025 to 2031. This growth is driven by advancements in viral engineering and a rising investment in cancer immunotherapy, addressing the high unmet medical needs in cancer treatment. The market encompasses various product types, including Vaccinia Virus-based and HSV-based oncolytic viruses, and serves applications across multiple cancer types such as breast and lung cancer. Notably, collaboration between pharmaceutical companies and research institutions is emerging as a key trend, enhancing the Oncolytic Virus Therapy Market share and fostering innovative treatment approaches. This Oncolytic Virus Therapy Market report provides a comprehensive analysis of these dynamics, highlighting the future potential of personalized medicine in oncology.


The Oncolytic Virus Therapy Market is expected to register a CAGR of 24.5% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.

The Oncolytic Virus Therapy Market report covers segmental analysis by Product Type (Vaccinia Virus-based Oncolytic Viruses, HSV-based Oncolytic Viruses, Adenoviruses-based Oncolytic Viruses, Newcastle Disease Virus-based Oncolytic Viruses, Vesicular Stomatitis Virus-based Oncolytic Viruses); Application (Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Brain Tumor, Blood Cancer); End User (Hospitals, Specialty Clinics, Cancer Research Institutes), and Geography (North America, Europe, Asia Pacific, and South and Central America). The global analysis is further broken down at the regional level and major countries

Purpose of the Report

The report Oncolytic Virus Therapy Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:

  • Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
  • Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
  • Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.

Oncolytic Virus Therapy Market Segmentation

Product Type

  • Vaccinia Virus-based Oncolytic Viruses
  • HSV-based Oncolytic Viruses
  • Adenoviruses-based Oncolytic Viruses
  • Newcastle Disease Virus-based Oncolytic Viruses
  • Vesicular Stomatitis Virus-based Oncolytic Viruses

Application

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Melanoma
  • Brain Tumor
  • Blood Cancer

End User

  • Hospitals
  • Specialty Clinics
  • Cancer Research Institutes

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Oncolytic Virus Therapy Market: Strategic Insights

oncolytic-virus-therapy-market
  • Get Top Key Market Trends of this report.
    This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Oncolytic Virus Therapy Market Growth Drivers

  • Advancements in Viral Engineering and Genetic Modifications: Technological advancements in genetic engineering and virology have improved the efficiency of oncolytic virus therapy. Scientists have achieved significant improvements in the manipulation and improvement of viruses to be more selective in attacking cancer cells while avoiding healthy tissues. Such innovations have resulted in more potent and effective oncolytic virus candidates, thus fueling market growth as new therapies come into clinical trials and are closer to commercialization.
  • Rising Investment in Cancer Immunotherapy: The growth of the Oncolytic Virus Therapy Market has been indirectly fueled by the growing interest in immunotherapy, especially in cancer immunotherapy. Oncolytic viruses help stimulate the body's immune response to identify and destroy cancerous cells, thereby strengthening the natural capabilities of the immune system. Investments in immunotherapy have been rising as it continues to attract both public and private investments, thus ever more promising as an alternative or standalone therapy in cancer.
  • Regulatory Approvals and Breakthrough Therapies: Regulatory approval for oncolytic virus therapies from such bodies as the U.S. Food and Drug Administration has helped the market grow faster. T-VEC, Talimogene laherparepvec, was the first oncolytic virus therapy that was given approval by the FDA in 2015 to treat melanoma. Such approvals have inspired many to research in this area in the recent past. Second, several oncolytic virus drugs have already gained breakthrough therapy designations of many, and this has enabled quicker approval of the treatment and, hence their quicker availability in the market.

Oncolytic Virus Therapy Market Future Trends

  • Collaboration Between Pharmaceutical Companies and Research Institutions: The pharmaceutical companies and research institution can hold very good collaborations that would propel oncolytic virus therapy. The companies can gather their respective resources and funding that come with relevant expertize, thus they will be beneficial in developing such therapies. It also gives scope to penetrate into markets faster because marketing in an accelerated pace gets into markets much quicker than normal circumstances.
  • High Unmet Medical Need in Cancer Treatment: The unmet need for more effective cancer treatment is left, especially among patients with advanced-stage cancers or those who did not respond to traditional treatments. Oncolytic virus therapy gives an innovative way of targeting and killing cancer cells without affecting normal tissue. The unmet need for more effective cancer treatments creates a demand for oncolytic virus therapies as the promising option for patients with few choices.
  • Patient-Specific and Personalized Medicine Approaches: The growth in the Oncolytic Virus Therapy Market can be attributed to the rising trend toward personalized medicine, whereby treatment is adapted according to an individual patient profile. The oncolytic viruses can be tailored with regard to specific types of cancer or even individual characteristics, thus delivering a more targeted and effective therapy. This shift towards precision oncology is giving way to enhanced adoption of oncolytic virus therapies.

Oncolytic Virus Therapy Market Opportunities

  • Combination Therapies with Immuno-Oncology Agents: Such treatment is believed to add an option to combine the OncoLytic Virus Therapy with other immuno-oncology drugs like checkpoint inhibitors, like PD-1/PD-L1 inhibitors and antibodies, thereby providing higher synergistic effects in treating diseases. Several clinical results of such studies are very promising, leading the door for potential better treatment by combination and better overall therapy and thereby expanded the scope of this market through high patient outcomes.
  • Development of Novel Oncolytic Virus Strains: The market for oncolytic virus therapy is all set to introduce innovative novel strains of viruses that may be used on a more diverse scope of cancers. Various viruses including engineered adenoviruses, herpes simplex viruses, and vesicular stomatitis viruses are also under research with respect to its ability to fight cancerous disorders. Availability of the new generation of highly specific and less harmful oncolytic viruses for application will further create large scope for greater applications of market share.
  • Integration with Gene Therapy Approaches: The combination of oncolytic virus therapy with gene therapy is a very exciting prospect. Oncolytic viruses can be genetically engineered to carry specific genes that enhance the immune response or directly attack cancer cells. This dual approach of viral infection and gene delivery may bring some groundbreaking treatments of hard-to-treat cancers, such as pancreatic or glioblastoma. That, in respect, is a good side of gene therapy-because it is bringing ever-increasing potential for boost in the functionalities of oncolytic viruses that propel the growth of the tumor as well as innovation in cancer treatment.

Oncolytic Virus Therapy Market Regional Insights

The regional trends and factors influencing the Oncolytic Virus Therapy Market throughout the forecast period have been thoroughly explained by the analysts at The Insight Partners. This section also discusses Oncolytic Virus Therapy Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Oncolytic Virus Therapy Market Report Scope

Report Attribute Details
Market size in 2024 US$ XX million
Market Size by 2031 US$ XX Million
Global CAGR (2025 - 2031) 24.5%
Historical Data 2021-2023
Forecast period 2025-2031
Segments Covered By Product Type
  • Vaccinia Virus-based Oncolytic Viruses
  • HSV-based Oncolytic Viruses
  • Adenoviruses-based Oncolytic Viruses
  • Newcastle Disease Virus-based Oncolytic Viruses
  • Vesicular Stomatitis Virus-based Oncolytic Viruses
By Application
  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Melanoma
  • Brain Tumor
  • Blood Cancer
By End User
  • Hospitals
  • Specialty Clinics
  • Cancer Research Institutes
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Amgen Inc
  • Oncolytics Biotech, Inc.
  • Merck & Co., Inc.
  • Transgene
  • Oncolys BioPharma Inc.
  • Targovax ASA
  • Vyriad Inc.
  • Genelux Corporation
  • Sorrento Therapeutics, Inc.
  • Lokon Pharma AB

  • Oncolytic Virus Therapy Market Players Density: Understanding Its Impact on Business Dynamics

    The Oncolytic Virus Therapy Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.


    oncolytic-virus-therapy-market-cagr

    • Get the Oncolytic Virus Therapy Market top key players overview

    Key Selling Points

    • Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Oncolytic Virus Therapy Market, providing a holistic landscape.
    • Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
    • Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
    • Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.

    The research report on the Oncolytic Virus Therapy Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.


    Frequently Asked Questions

    1
    What is the expected CAGR of the Oncolytic Virus Therapy Market?
    The Oncolytic Virus Therapy Market is expected to register a CAGR of 24.5% from 2025-2031.
    2
    What are the driving factors impacting the Oncolytic Virus Therapy Market?
    The major factors impacting the Oncolytic Virus Therapy Market are: Advancements in Viral Engineering and Genetic Modifications, Rising Investment in Cancer Immunotherapy and Regulatory Approvals and Breakthrough Therapies
    3
    What are the future trends in the Oncolytic Virus Therapy Market?
    Key future trends in this market are - Collaboration Between Pharmaceutical Companies and Research Institutions, High Unmet Medical Need in Cancer Treatment and Patient-Specific and Personalized Medicine Approaches
    4
    Which are the key players in the Oncolytic Virus Therapy Market?
    Key companies of this market are: Amgen Inc, Oncolytics Biotech, Inc., Merck & Co., Inc., Transgene, Oncolys BioPharma Inc., Targovax ASA, Vyriad Inc., Genelux Corporation, Sorrento Therapeutics, Inc., Lokon Pharma AB
    5
    What are the deliverable formats of Oncolytic Virus Therapy Market report?
    The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
    6
    What are the options available for the customization of this report?
    Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
    Mrinal Kerhalkar
    Manager,
    Market Research & Consulting

    Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

    Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

    • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
    • PEST and SWOT Analysis
    • Market Size Value / Volume - Global, Regional, Country
    • Industry and Competitive Landscape
    • Excel Dataset

    Testimonials

    Reason to Buy

    • Informed Decision-Making
    • Understanding Market Dynamics
    • Competitive Analysis
    • Identifying Emerging Markets
    • Customer Insights
    • Market Forecasts
    • Risk Mitigation
    • Boosting Operational Efficiency
    • Strategic Planning
    • Investment Justification
    • Tracking Industry Innovations
    • Aligning with Regulatory Trends
    Your Key Concerns Addressed - Question & Answer
    Can I view a sample of the report before purchasing?

    Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.

    Is analyst support included with the purchase?

    Absolutely — analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.

    What are the next steps once I place an order?

    Once your order is successfully placed, you will receive a confirmation email along with your invoice.

    • For published reports: You’ll receive access to the report within 4–6 working hours via a secured email sent to your email.
    • For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.

    Can the report be tailored to suit my specific needs?

    We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we’ll be happy to provide a customized proposal or scope.

    In what format is the report delivered?

    The report is available in either PDF format or as an Excel dataset, depending on the license you choose.

    The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
    Please review the license options at checkout or contact us to confirm which formats are included with your purchase.

    How secure is the payment process on your platform?

    Our payment process is fully secure and PCI-DSS compliant.

    We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
    You can make your purchase with confidence, knowing your personal and financial information is safe with us.

    Do you provide special pricing for buying multiple reports?

    Yes, we do offer special pricing for bulk purchases.
    If you're interested in purchasing multiple reports, we’re happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you’re considering, and we’ll share a personalized quote.

    Can I connect with your team to discuss the report before buying?

    Yes, absolutely.
    Our team is available to help you make an informed decision. Whether you have questions about the report’s scope, methodology, customization options, or which license suits you best, we’re here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.

    Will I get a billing invoice upon purchase?

    Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
    If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we’ll be happy to assist.

    Is there support available if I can’t access my report?

    Yes, certainly.
    If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we’ll ensure the issue is resolved quickly so you can access your report without interruption.

    Our Clients
    The List of Companies

    1. Amgen Inc
    2. Oncolytics Biotech, Inc.
    3. Merck & Co., Inc.
    4. Transgene
    5. Oncolys BioPharma Inc.
    6. Targovax ASA
    7. Vyriad Inc.
    8. Genelux Corporation
    9. Sorrento Therapeutics, Inc.
    10. Lokon Pharma AB
    Sales Assistance
    US: +1-646-491-9876
    UK: +44-20-8125-4005
    Email: sales@theinsightpartners.com
    Chat with us
    DUNS Logo
    87-673-9708
    ISO Certified Logo
    ISO 9001:2015
    ISO Certified Logo